骨髓增生异常综合征的分子分类及其临床意义
该研究对3233例骨髓增生异常综合征(MDS)或相关疾病患者进行152基因靶向测序,识别出16个分子分组(覆盖86%患者),各组骨髓原始细胞中位数1.5%–10%、总生存中位数0.9–8.2年,并验证5个已知实体、支持3个既往亚组、描述8个新分组。
要点
- 152基因靶向测序在91%患者中检出基因突变,43%检出拷贝数改变,11%检出拷贝中性杂合性缺失。
- 16个分子分组覆盖86%患者,大小0.5%–14%,与不同临床表型和结局相关。
- 骨髓原始细胞百分比的预后影响取决于遗传亚型。
核心结论
- 遗传学衍生的MDS亚组具有临床相关性,可能为未来分类方案和转化治疗研究提供信息。
研究设计与样本
- 对3233例MDS或相关疾病患者进行152基因靶向测序的基因组分析,以 delineate 分子亚型并定义其临床意义。
主要发现
- 基因突变、拷贝数改变和拷贝中性杂合性缺失分别见于91%、43%和11%的患者。
- 利用21个基因、6种细胞遗传学事件及TP53和TET2位点杂合性缺失信息,识别出16个分子分组,覆盖86%患者。
- 两个由阴性发现定义的残留组(分子学非特指、无复发性驱动事件)占14%患者。
- 各组骨髓原始细胞百分比中位数为1.5%至10%,总生存中位数范围为0.9至8.2年。
- 验证了5个特征明确的实体,为3个既往报道的亚组增加证据,并描述了8个新分组;骨髓原始细胞的预后影响取决于遗传亚型。
关键数值与推荐
- 在遗传亚组内,治疗相关MDS和骨髓增生异常/骨髓增殖性肿瘤具有与原发性MDS相当的临床和结局特征。
临床怎么用
- 遗传学衍生的MDS亚组具有临床相关性,可能为未来分类方案和转化治疗研究提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by morphologic abnormalities of myeloid cells and peripheral cytopenias. Although genetic abnormalities underlie the pathogenesis of these disorders and their heterogeneity, current classifications of MDS rely predominantly on morphology. We performed genomic profiling of 3233 patients with MDS or related disorders to delineate molecular subtypes and define their clinical implications. Gene mutations, copy-number alterations, and copy-neutral loss of heterozygosity were derived from targeted sequencing of a 152-gene panel, with abnormalities identified in 91%, 43%, and 11% of patients, respectively. We characterized 16 molecular groups, encompassing 86% of patients, using information from 21 genes, 6 cytogenetic events, and loss of heterozygosity at the TP53 and TET2 loci. Two residual groups defined by negative findings (molecularly not otherwise specified, absence of recurrent drivers) comprised 14% of patients. The groups varied in size from 0.5% to 14% of patients and were associated with distinct clinical phenotypes and outcomes. The median bone marrow (BM) blast percentage across groups ranged from 1.5% to 10%, and the median overall survival ranged from 0.9 to 8.2 years. We validated 5 well-characterized entities, added further evidence to support 3 previously reported subsets, and described 8 novel groups. The prognostic influence of BM blasts depended on the genetic subtypes. Within genetic subgroups, therapy-related MDS and myelodysplastic/myeloproliferative neoplasms had comparable clinical and outcome profiles to primary MDS. In conclusion, genetically-derived subgroups of MDS are clinically relevant and might inform future classification schemas and translational therapeutic research.
引用
- Bernard E, Hasserjian RP, Greenberg PL, et al. Molecular taxonomy of myelodysplastic syndromes and its clinical implications. Blood. 2024. PMID: 38958467. doi:10.1182/blood.2023023727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。